Procedure for assessing the acceptability, in principle, of vaccines ...

More documents

Recommendations

Info

74 WHO/BS/10.2155 Page 74 meeting or work related to the declared interest and from the corresponding decision making process); or (iii) mandates total exclusion (i.e. you will not be able to participate in any part of the meeting or work). All potentially significant interests will be disclosed to the other participants at the start of the activity and you will be asked if there have been any changes. A summary of all declarations and actions taken to manage any declared interests will be published in resulting reports and work products. Furthermore, if the objectivity of the work or meeting in which you are involved is subsequently questioned, the contents of your DOI form may be made available by the Secretariat to persons outside WHO if the Director-General considers such disclosure to be in the best interest of the Organization, after consulting with you. Completing this DOI form means that you agree to these conditions. If you are unable or unwilling to disclose the details of an interest that may pose a real or perceived conflict, you must disclose that a conflict of interest may exist and the Secretariat may decide that you be totally recused from the meeting or work concerned, after consulting with you. Name: ________________________________________ Institution: ____________________________________ Email: ________________________________________ Date and title of meeting or work, including description of subject matter to be considered (if a number of substances or processes are to be evaluated, a list should be attached by the organizer of the activity): _____________________________________________________________________________ ___________________________________________________________________ Please answer each of the questions below. If the answer to any of the questions is "yes", briefly describe the circumstances on the last page of the form. The term "you" refers to yourself and your immediate family members (i.e. spouse (or partner with whom you have a similar close personal relationship) and your children). "Commercial entity" includes any commercial business, an industry association, research institution or other enterprise whose funding is significantly derived from commercial sources with an interest related to the subject of the
75 WHO/BS/10.2155 Page 75 meeting or work. "Organization" includes a governmental, international or non-profit organization. "Meeting" includes a series or cycle of meetings. EMPLOYMENT AND CONSULTING Within the past 4 years, have you received remuneration from a commercial entity or other organization with an interest related to the subject of the meeting or work? 1a Employment Yes/No 1b Consulting, including service as a technical or other advisor Yes/No RESEARCH SUPPORT Within the past 4 years, have you or has your research unit received support from a commercial entity or other organization with an interest related to the subject of the meeting or work? 2a Research support, including grants, collaborations, sponsorships, and other funding Yes/No 2b Non-monetary support valued at more than US $1000 overall (include equipment, facilities, research assistants, paid travel to meetings, etc. Support (including honoraria) for being on a speakers bureau, giving speeches or training for a commercial entity or other organization with an interest related to the subject of the meeting or work? Yes/No INVESTMENT INTERESTS Do you have current investments (valued at more than US $10 000 overall) in a commercial entity with an interest related to the subject of the meeting or work? Please also include indirect investments such as a trust or holding company. You may exclude mutual funds, pension funds or similar investments that are broadly diversified and on which you exercise no control. 3a Stocks, bonds, stock options, other securities (e.g. short sales) Yes/No 3b Commercial business interests (e.g. proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company) Yes/No INTELLECTUAL PROPERTY Do you have any intellectual property rights that might be enhanced or diminished by the outcome of
Page 1 and 2:
Procedure for assessing the accepta
Page 3 and 4:
Acronyms The following acronyms are
Page 5 and 6:
The prequalification procedure esta
Page 7 and 8:
• The candidate vaccine meets the
Page 9 and 10:
Such meetings are important for dis
Page 11 and 12:
immunization programmes and vaccine
Page 13 and 14:
As soon as the PSF is accepted and
Page 15 and 16:
manufacturer, to organize an abbrev
Page 17 and 18:
with both the WHO requirements and
Page 19 and 20:
o review and approval of variations
Page 21 and 22:
− confirmation that the vaccine m
Page 23 and 24: collaborative effort. Special atten
Page 25 and 26: for submission of PSFs do not apply
Page 27 and 28: In cases where the vaccine manufact
Page 29 and 30: WHO reserves the right to take appr
Page 31 and 32: C. The manufacturer should provide
Page 33 and 34: If, as a result of the reassessment
Page 35 and 36: In the event of situations as descr
Page 37 and 38: identifying the confidential inform
Page 39 and 40: Authors The proposals for the revis
Page 41 and 42: Geneva, Switzerland; Dr U Rosskopf,
Page 43 and 44: Acknowledgments Acknowledgements ar
Page 46 and 47: Appendix 1 The product summary file
Page 48 and 49: 3.3 Describe ventilation systems in
Page 50 and 51: For recombinant vaccines, a descrip
Page 52 and 53: 7.3 Provide information on stabilit
Page 54 and 55: particular attention to any data th
Page 56 and 57: 9.3 Summarize the arrangements and
Page 58 and 59: Appendix 2 Flowcharts of WHO prequa
Page 60 and 61: Request/supply of Additional Data Y
Page 62 and 63: Satisfactory Completion of PSF revi
Page 64 and 65: 4 5 oversight. Validation of the cr
Page 66 and 67: 9 10 the critical tests • Review
Page 68 and 69: 68 WHO/BS/10.2155 Page 68 1) An app
Page 70 and 71: 70 WHO/BS/10.2155 Page 70 http://ww
Page 72 and 73: 72 WHO/BS/10.2155 Page 72 1) may ha
Page 76 and 77: the meeting or work? 4a Patents, tr
Page 78: true and complete to the best of my
show all

Procedure for assessing the acceptability, in principle, of vaccines ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?